BioMarin Pharmaceutical Inc.  

(Public, NASDAQ:BMRN)   Watch this stock  
Find more results for BMRN
91.53
+3.35 (3.80%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 88.09 - 91.74
52 week 55.04 - 96.36
Open 88.86
Vol / Avg. 572,725.00/1.22M
Mkt cap 13.03B
P/E     -
Div/yield     -
EPS -0.88
Shares 147.47M
Beta 0.95
Inst. own 102%
Feb 24, 2015
Q4 2014 Biomarin Pharmaceutical Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 10, 2014
Biomarin Pharmaceutical Inc Analyst and Investor Day
Dec 3, 2014
Biomarin Pharmaceutical Inc at Piper Jaffray Healthcare Conference
Dec 2, 2014
Biomarin Pharmaceutical Inc at Deutsche Bank BioFEST
Nov 24, 2014
Biomarin Pharmaceutical Inc and Prosensa Holding NV Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock Call
Nov 11, 2014
Biomarin Pharmaceutical Inc at Credit Suisse Healthcare Conference
Nov 4, 2014
Biomarin Pharmaceutical Inc at EBD Group BIO-Europe Conference
Oct 23, 2014
Q3 2014 Biomarin Pharmaceutical Inc Earnings Call
Oct 23, 2014
Q3 2014 Biomarin Pharmaceutical Inc Earnings Release
Oct 1, 2014
Biomarin Pharmaceutical Inc at Leerink Rare Disease Roundtable
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.21% -32.15%
Operating margin 6.33% -30.81%
EBITD margin - -18.93%
Return on average assets 1.25% -9.25%
Return on average equity 2.01% -14.97%
Employees 1,341 -
CDP Score - -

Address

105 DIGITAL DRIVE
NOVATO, CA 94949
United States - Map
+1-415-5066700 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioMarin Pharmaceutical Inc. (BioMarin) develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company�s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). It is conducting clinical trials on several product candidates for the treatment of various diseases. They include Vimizim (formerly referred to as GALNS), an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonuria (PKU), and BMN-701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder. On January 7, 2013, the Company acquired Zacharon Pharmaceuticals.

Officers and directors

Pierre Lapalme Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jean-Jacques Bienaime Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Daniel K. Spiegelman Chief Financial Officer, Executive Vice President
Age: 55
Bio & Compensation  - Reuters
Jeff Robert Ajer Executive Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Robert A. Baffi Ph.D. Executive Vice President - Technical Operations
Age: 59
Bio & Compensation  - Reuters
Henry J. Fuchs M.D., Ph.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
G. Eric Davis Senior Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Richard J. Ranieri Senior Vice President - Human Resources and Corporate Affairs
Age: 60
Bio & Compensation  - Reuters
Brian R. Mueller Group Vice President, Corporate Controller
Age: 40
Bio & Compensation  - Reuters
Dennis J. Slamon M.D., Ph.D. Director
Age: 65
Bio & Compensation  - Reuters